Seeking Alpha

Smith On Stocks'  Instablog

Smith On Stocks
Send Message
Follow @SmithOnStocks on Twitter for more updates (http://twitter.com/#SmithOnStocks Please read this section carefully for some important disclosures. Who Am I? My name is Larry Smith. My career was spent on Wall Street as a biotechnology and pharmaceuticals analyst and also as Director of... More
My company:
SmithOnStocks.com
My blog:
Smith On Stocks
View Smith On Stocks' Instablogs on:
  • Comments On Data Presented By Northwest Biotherapeutics On DCVax Direct At ASCO

    I have been going over data presented at ASCO on immune-oncology products and have been listening carefully to the presentations by Northwest Biotherapeutics (NASDAQ:NWBO) and other companies active in this space, particularly Bristol-Myers Squibb (NYSE:BMY) and Merck (NYSE:MRK). Let me summarize some of my key takeaways which will be addressed in more detail later.

    • The presentations of Merck and Bristol-Myers Squibb suggested that their checkpoint inhibitors could be synergistic with cancer vaccines. This provides important third party validation of the promise of cancer vaccines in the treatment of cancer. Wall Street analysts and investors have been skeptical on cancer vaccines. I can see the possibility of a one hundred and eighty degree turn from disinterest to excitement.
    • If my speculation is correct, Bristol-Myers Squibb or Merck or perhaps some other checkpoint inhibitor drug developers could form collaborations in coming months with Northwest for DCVax-L© or DCVax-Direct© or both. This would be very important validation for NWBO's drugs. My guess is that Bristol-Myers is likely to be the first to form a collaboration.
    • There is a reasonable hypothesis that suggests very strong synergy between DCVax-Direct© and checkpoint inhibition which in the most optimistic of many possible scenarios might make this combination the backbone of many solid tumor treatments.
    • I think that it would make great deal of sense to combine DCVax-Direct© with Opdivo in the treatment of non-small cell lung cancer as Opdivo is already approved for this indication. Improvement of the combination over Opdivo even in a small study could lead to a BLA filing.
    • Northwest has the potential to undertake many important new trials with DCVax-L© and DCVax-Direct©. The question is how will they fund these trials; the shorts have been betting heavily that Northwest either won't be able to raise money or will have to do so on onerous terms. They could be wrong. Neil Woodford has already invested $65 million in Northwest by purchases of securities issued by the Company and has purchased an estimated additional $35 million in the open market. This money is not just being invested from one of his funds. It may be the case that he has a continued appetite for the stock and can continue to provide additional funding going forward and on favorable terms.

    The complete report is available on my website.

    Tags: NWBO
    Jun 08 8:47 AM | Link | 1 Comment
  • A Detailed Sales And Profit Model For Antares

    I believe that 2015 could be a breakout year for the stock of Antares. I have written a detailed report on my website explaining the underlying assumptions that result in the detailed model below. The full report on my website requires a subscription of $149.99 per year or $24.99 for a month,

    (click to enlarge)

    Tags: ATRS
    Apr 23 10:02 AM | Link | Comment!
  • Northwest Biotherapeutics: Analysis Of Promising New Data Was Just Presented On DCVax-L In Recurrent Glioblastoma Multiforme

    Northwest Biotherapeutics has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed glioblastoma multiforme. They became ineligible when their cancer progressed before they could enter the trial. However, they were treated nearly identically to the 348 patients and followed to see how long they survived; the survival data was striking. This increases the expectation for success in the ongoing phase 3 trial.

    The complete 22 page report is available at this link.

    smithonstocks.com/northwest-biotherapeut.../

    Tags: NWBO
    Mar 27 9:50 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.